A Phase 3 interventional study of F/TAF and F/TDF in Pre-Exposure Prophylaxis of HIV-1 Infection, sponsored by Gilead Sciences. Terminated at 93 sites in 11 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to assess the rates of HIV-1 infection in Men (MSM) and transgender women (TGW) who have sex with men and who are administered daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) with a minimum follow-up of 48 weeks and at least 50% of participants have 96 weeks of follow-up after randomization.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
MSM and TGW (male at birth) who have at least one of the following:
Adequate liver and hematologic function:
Key Exclusion Criteria
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
F/TAF+ F/TDF placebo for at least 96 weeks
Drug: F/TAF · Drug: F/TDF Placebo
F/TDF+ F/TAF placebo for at least 96 weeks
Drug: F/TDF · Drug: F/TAF Placebo
Once all participants have been on blinded treatment for at least 96 weeks, the study will be unblinded and participants will be offered the option to continue on open-label F/TAF treatment for 96 weeks.
Drug: F/TAF
Participants who remain on study at Open-label Week 96 will have the option to continue on open-label F/TAF treatment in the Open-label extension phase for 408 weeks.
Drug: F/TAF
Drug pages: Emtricitabine · Tenofovir alafenamide
200/25 mg tablet administered orally once daily
Also known as: Descovy®
200/300 mg tablet administered orally once daily
Also known as: Truvada®
Tablet administered orally once daily
Tablet administered orally once daily
Incidence of HIV-1 Infection Per 100 Person Years (PY)
The incidence of HIV-1 infection rate per 100 PY was calculated as the number of participants who became HIV infected during the study after the first dose of study drug divided by the sum of all participants' years (where a year is 365.25 days) of follow-up while at risk of HIV infection during the study. HIV-1 infection is defined by one or more of the following criteria of contributing HIV tests performed via central lab or local lab: * Serologic evidence of seroconversion (reactive screening HIV Antigen/Antibody or Antibody test, confirmed by reactive HIV-1/HIV-2 differentiation assay), excluding HIV vaccinated participants, or * Virologic evidence of HIV-1 infection (positive qualitative HIV-1 RNA test or any detectable quantitative HIV-1 RNA test), or * Evidence of acute HIV-1 infection (reactive p24 Antigen or positive qualitative or quantitative RNA, in the absence of reactive HIV-1 Antibody results)
Time frame: When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 in the Blinded Phase
Percent Change = Change from baseline at Week 48 visit/value at baseline \* 100%.
Time frame: Baseline, Week 48
Percent Change From Baseline in Spine BMD at Week 48 in the Blinded Phase
Percent Change = Change from baseline at Week 48 visit/value at baseline \* 100%.
Time frame: Baseline, Week 48
Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 48 in the Blinded Phase
Percent Change = Change from baseline at Week 48 visit/value at baseline \* 100%. For urine creatinine, value of \< 1 was handled as a missing value in its summary and the calculation of related ratios.
Time frame: Baseline, Week 48
Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48 in the Blinded Phase
Percent Change = Change from baseline at Week 48 visit/value at baseline \* 100%. For urine creatinine, value of \< 1 was handled as a missing value in its summary and the calculation of related ratios.
Time frame: Baseline, Week 48
Number of Participants by Urine Protein (UP) and Urine Protein to Creatinine Ratio (UPCR) Categories at Week 48 in the Blinded Phase
The UPCR was only calculated when corresponding UP ≥ 4.0 mg/dL. The UPCR "≤ 200 mg/g" category includes both participants with UP \< 4.0 mg/dL and participants with UPCR ≤ 200 mg/g.
Time frame: Baseline, Week 48
Change From Baseline in Serum Creatinine at Week 48 in the Blinded Phase
Time frame: Baseline, Week 48
Incidence of HIV-1 Infection Per 100 PY
The incidence of HIV-1 infection rate per 100 PY was calculated as the number of participants who became HIV infected during the study after the first dose of study drug divided by the sum of all participants' years (where a year is 365.25 days) of follow-up while at risk of HIV infection during the study. HIV-1 infection is defined by one or more of the following criteria of contributing HIV tests performed via central lab or local lab: * Serologic evidence of seroconversion (reactive screening HIV Antigen/Antibody or Antibody test, confirmed by reactive HIV-1/HIV-2 differentiation assay), excluding HIV vaccinated participants, or * Virologic evidence of HIV-1 infection (positive qualitative HIV-1 RNA test or any detectable quantitative HIV-1 RNA test), or * Evidence of acute HIV-1 infection (reactive p24 Antigen or positive qualitative or quantitative RNA, in the absence of reactive HIV-1 Antibody results)
Time frame: When all participants have 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 157 weeks)
Percent Change From Baseline in Hip BMD at Week 96 in the Blinded Phase
Percent Change = Change from baseline at Week 96 visit/value at baseline \* 100%.
Time frame: Baseline, Week 96
Percent Change From Baseline in Spine BMD at Week 96 in the Blinded Phase
Percent Change = Change from baseline at Week 96 visit/value at baseline \* 100%.
Time frame: Baseline, Week 96
Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 96 in the Blinded Phase
Percent Change = Change from baseline at Week 96 visit/value at baseline \* 100%. For urine creatinine, value of \< 1 was handled as a missing value in its summary and the calculation of related ratios.
Time frame: Baseline, Week 96
Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96 in the Blinded Phase
Percent Change = Change from baseline at Week 96 visit/value at baseline \* 100%. For urine creatinine, value of \< 1 was handled as a missing value in its summary and the calculation of related ratios.
Time frame: Baseline, Week 96
Number of Participants by UP and UPCR Categories at Week 96 in the Blinded Phase
The UPCR was only calculated when corresponding UP ≥ 4.0 mg/dL. The UPCR "≤ 200 mg/g" category includes both participants with UP \< 4.0 mg/dL and participants with UPCR ≤ 200 mg/g.
Time frame: Baseline, Week 96
Change From Baseline in Serum Creatinine at Week 96 in the Blinded Phase
Time frame: Baseline, Week 96
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
Time frame: First dose date up to the data cut for end of blinded treatment (maximum: 157 weeks)
Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality
Time frame: First dose date up to the data cut for end of blinded treatment (maximum: 157 weeks)
Participants were enrolled at study sites in the United States, Canada, and the European Union. The first participant was screened on 02 September 2016. The data cut date for the end of blinded treatment phase was 12 December 2019.
| Milestone | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| Started | 2700 | 2699 |
| Completed | 2156 | 2206 |
| Not completed | 544 | 493 |
| Withdrew: Randomized but never treated | 6 | 6 |
| Withdrew: Still in double-blind phase | 7 | 3 |
| Withdrew: Adverse event | 18 | 20 |
| Withdrew: Death | 3 | 3 |
| Withdrew: Investigator's discretion | 9 | 13 |
| Withdrew: Non-compliance with study drug | 9 | 8 |
| Withdrew: Protocol violation | 8 | 4 |
| Withdrew: Withdrew consent | 205 | 194 |
| Withdrew: Lost to follow-up | 274 | 236 |
| Withdrew: Hiv-1 infection | 5 | 6 |
The incidence of HIV-1 infection rate per 100 PY was calculated as the number of participants who became HIV infected during the study after the first dose of study drug divided by the sum of all participants' years (where a year is 365.25 days) of follow-up while at risk of HIV infection during the study. HIV-1 infection is defined by one or more of the following criteria of contributing HIV tests performed via central lab or local lab: * Serologic evidence of seroconversion (reactive screening HIV Antigen/Antibody or Antibody test, confirmed by reactive HIV-1/HIV-2 differentiation assay), excluding HIV vaccinated participants, or * Virologic evidence of HIV-1 infection (positive qualitative HIV-1 RNA test or any detectable quantitative HIV-1 RNA test), or * Evidence of acute HIV-1 infection (reactive p24 Antigen or positive qualitative or quantitative RNA, in the absence of reactive HIV-1 Antibody results)
| HIV-1 infections per 100 PY | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| Incidence of HIV-1 Infection Per 100 Person Years (PY) | 0.160 (0.064 to 0.330) | 0.342 (0.191 to 0.564) |
Percent Change = Change from baseline at Week 48 visit/value at baseline \* 100%.
| Percent Change | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 in the Blinded Phase | 0.218 ± 2.3668 | -0.968 ± 2.4343 |
Percent Change = Change from baseline at Week 48 visit/value at baseline \* 100%.
| Percent Change | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 48 in the Blinded Phase | 0.512 ± 2.9854 | -1.061 ± 2.9382 |
Percent Change = Change from baseline at Week 48 visit/value at baseline \* 100%. For urine creatinine, value of \< 1 was handled as a missing value in its summary and the calculation of related ratios.
| Percent Change | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 48 in the Blinded Phase | -10.6 (-42.0 to 25.9) | 15.4 (-22.9 to 97.2) |
Percent Change = Change from baseline at Week 48 visit/value at baseline \* 100%. For urine creatinine, value of \< 1 was handled as a missing value in its summary and the calculation of related ratios.
| Percent Change | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48 in the Blinded Phase | 0.1 (-24.9 to 35.3) | 20.0 (-13.0 to 68.2) |
The UPCR was only calculated when corresponding UP ≥ 4.0 mg/dL. The UPCR "≤ 200 mg/g" category includes both participants with UP \< 4.0 mg/dL and participants with UPCR ≤ 200 mg/g.
| Participants | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| ≤ 200 mg/g at Baseline; ≤ 200 mg/g at Week 48 | 2318 | 2295 |
| ≤ 200 mg/g at Baseline; > 200 mg/g at Week 48 | 16 | 35 |
| > 200 mg/g at Baseline; ≤ 200 mg/g at Week 48 | 12 | 8 |
| > 200 mg/g at Baseline; > 200 mg/g at Week 48 | 9 | 10 |
| mg/dL | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| Change From Baseline in Serum Creatinine at Week 48 in the Blinded Phase | -0.01 ± 0.107 | 0.01 ± 0.111 |
The incidence of HIV-1 infection rate per 100 PY was calculated as the number of participants who became HIV infected during the study after the first dose of study drug divided by the sum of all participants' years (where a year is 365.25 days) of follow-up while at risk of HIV infection during the study. HIV-1 infection is defined by one or more of the following criteria of contributing HIV tests performed via central lab or local lab: * Serologic evidence of seroconversion (reactive screening HIV Antigen/Antibody or Antibody test, confirmed by reactive HIV-1/HIV-2 differentiation assay), excluding HIV vaccinated participants, or * Virologic evidence of HIV-1 infection (positive qualitative HIV-1 RNA test or any detectable quantitative HIV-1 RNA test), or * Evidence of acute HIV-1 infection (reactive p24 Antigen or positive qualitative or quantitative RNA, in the absence of reactive HIV-1 Antibody results)
| HIV-1 infections per 100 PY | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| Incidence of HIV-1 Infection Per 100 PY | 0.159 (0.069 to 0.313) | 0.297 (0.166 to 0.490) |
Percent Change = Change from baseline at Week 96 visit/value at baseline \* 100%.
| Percent Change | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| Percent Change From Baseline in Hip BMD at Week 96 in the Blinded Phase | 0.565 ± 2.9379 | -1.048 ± 2.9277 |
Percent Change = Change from baseline at Week 96 visit/value at baseline \* 100%.
| Percent Change | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 96 in the Blinded Phase | 0.831 ± 3.4608 | -1.426 ± 3.5508 |
Percent Change = Change from baseline at Week 96 visit/value at baseline \* 100%. For urine creatinine, value of \< 1 was handled as a missing value in its summary and the calculation of related ratios.
| Percent Change | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 96 in the Blinded Phase | -14.5 (-45.4 to 23.9) | 14.1 (-26.2 to 99.5) |
Percent Change = Change from baseline at Week 96 visit/value at baseline \* 100%. For urine creatinine, value of \< 1 was handled as a missing value in its summary and the calculation of related ratios.
| Percent Change | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96 in the Blinded Phase | 0.3 (-27.1 to 35.7) | 21.4 (-13.8 to 73.9) |
The UPCR was only calculated when corresponding UP ≥ 4.0 mg/dL. The UPCR "≤ 200 mg/g" category includes both participants with UP \< 4.0 mg/dL and participants with UPCR ≤ 200 mg/g.
| Participants | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| ≤ 200 mg/g at Baseline; ≤ 200 mg/g at Week 96 | 2134 | 2153 |
| ≤ 200 mg/g at Baseline; > 200 mg/g at Week 96 | 21 | 28 |
| > 200 mg/g at Baseline; ≤ 200 mg/g at Week 96 | 14 | 10 |
| > 200 mg/g at Baseline; > 200 mg/g at Week 96 | 6 | 8 |
| mg/dL | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| Change From Baseline in Serum Creatinine at Week 96 in the Blinded Phase | 0.01 ± 0.114 | 0.03 ± 0.117 |
| percentage of participants | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events | 93.7 | 93.6 |
| percentage of participants | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality | 76.1 | 79.1 |
Collected over First dose date up to the data cut for end of blinded treatment (maximum: 157 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Descovy (DVY) | 3/2,694 (0.1%) | 202/2,694 (7.5%) | 2,258/2,694 (83.8%) |
| Truvada (TVD) | 3/2,693 (0.1%) | 186/2,693 (6.9%) | 2,229/2,693 (82.8%) |
| Event | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| AppendicitisInfections and infestations | 9/2694 | 10/2693 |
| Suicidal ideationPsychiatric disorders | 8/2694 | 5/2693 |
| Atrial fibrillationCardiac disorders | 2/2694 | 7/2693 |
| CellulitisInfections and infestations | 7/2694 | 5/2693 |
| Acute kidney injuryRenal and urinary disorders | 7/2694 | 2/2693 |
| Hepatitis AInfections and infestations | 6/2694 | 2/2693 |
| PneumoniaInfections and infestations | 5/2694 | 4/2693 |
| DepressionPsychiatric disorders | 5/2694 | 3/2693 |
| Suicide attemptPsychiatric disorders | 5/2694 | 1/2693 |
| Chest painGeneral disorders | 2/2694 | 4/2693 |
| Event | Descovy (DVY) | Truvada (TVD) |
|---|---|---|
| Anal chlamydia infectionInfections and infestations | 890/2694 | 902/2693 |
| Oropharyngeal gonococcal infectionInfections and infestations | 871/2694 | 838/2693 |
| Proctitis gonococcalInfections and infestations | 805/2694 | 797/2693 |
| Exposure to communicable diseaseInjury, poisoning and procedural complications | 554/2694 | 548/2693 |
| DiarrhoeaGastrointestinal disorders | 479/2694 | 451/2693 |
| SyphilisInfections and infestations | 413/2694 | 392/2693 |
| NasopharyngitisInfections and infestations | 399/2694 | 402/2693 |
| Upper respiratory tract infectionInfections and infestations | 402/2694 | 346/2693 |
| Urethritis chlamydialInfections and infestations | 346/2694 | 314/2693 |
| Urethritis gonococcalInfections and infestations | 259/2694 | 255/2693 |
The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug. Participants were grouped according to the treatment they actually received.
| Age, Continuous(years) | Descovy (DVY) | Truvada (TVD) | Total |
|---|---|---|---|
| Mean | 36 ± 10.6 | 36 ± 10.7 | 36 ± 10.6 |
| Sex/Gender, Customized(Participants) | Descovy (DVY) | Truvada (TVD) | Total |
|---|---|---|---|
| Transgender Women | 45 | 29 | 74 |
| Sex: Female, Male(Participants) | Descovy (DVY) | Truvada (TVD) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 2694 | 2693 | 5387 |
| Race/Ethnicity, Customized(Participants) | Descovy (DVY) | Truvada (TVD) | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 12 | 14 | 26 |
| Race — Asian | 113 | 120 | 233 |
| Race — Black/Mixed Black | 240 | 234 | 474 |
| Race — Native Hawaiian or Pacific Islander | 17 | 23 | 40 |
| Race — White | 2264 | 2247 | 4511 |
| Race — Other (Nonblack) | 45 | 50 | 95 |
| Race — Not Permitted | 3 | 5 | 8 |
| Race/Ethnicity, Customized(Participants) | Descovy (DVY) | Truvada (TVD) | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 635 | 683 | 1318 |
| Ethnicity — Not Hispanic or Latino | 2058 | 2008 | 4066 |
| Ethnicity — Not Permitted | 1 | 2 | 3 |
| Region of Enrollment(Participants) | Descovy (DVY) | Truvada (TVD) | Total |
|---|---|---|---|
| Canada | 191 | 162 | 353 |
| Austria | 35 | 42 | 77 |
| Denmark | 98 | 104 | 202 |
| France | 18 | 14 | 32 |
| Germany | 187 | 183 | 370 |
| Ireland | 40 | 38 | 78 |
| Italy | 37 | 21 | 58 |
| Netherlands | 31 | 40 | 71 |
| Spain | 219 | 195 | 414 |
| United Kingdom | 247 | 265 | 512 |
| United States | 1591 | 1629 | 3220 |
| Hip Bone Mineral Density (BMD)(g/cm^2) | Descovy (DVY) | Truvada (TVD) | Total |
|---|---|---|---|
| Mean | 1.030 ± 0.1553 | 1.021 ± 0.1322 | 1.025 ± 0.1443 |
| Spine BMD(g/cm^2) | Descovy (DVY) | Truvada (TVD) | Total |
|---|---|---|---|
| Mean | 1.134 ± 0.1646 | 1.131 ± 0.1381 | 1.132 ± 0.1518 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion and at least 6 months after the FDA and EMA approval
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from Sep 2016 to primary completion in Jan 2019, 28 months.
Results were first posted in Mar 2020, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Emtricitabine · Tenofovir alafenamide